pd 145065 has been researched along with atrasentan in 1 studies
| Studies (pd 145065) | Trials (pd 145065) | Recent Studies (post-2010) (pd 145065) | Studies (atrasentan) | Trials (atrasentan) | Recent Studies (post-2010) (atrasentan) |
|---|---|---|---|---|---|
| 76 | 1 | 5 | 358 | 41 | 108 |
| Protein | Taxonomy | pd 145065 (IC50) | atrasentan (IC50) |
|---|---|---|---|
| Endothelin receptor type B | Homo sapiens (human) | 0.2221 | |
| Endothelin-1 receptor | Homo sapiens (human) | 0.0001 | |
| Endothelin-1 receptor | Rattus norvegicus (Norway rat) | 0.0002 | |
| Endothelin receptor type B | Sus scrofa (pig) | 0.315 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alexiou, K; Baumann, G; Dschietzig, T; Laule, M; Schrör, K; Stangl, K | 1 |
1 other study(ies) available for pd 145065 and atrasentan
| Article | Year |
|---|---|
Coronary constriction and consequent cardiodepression in pulmonary embolism are mediated by pulmonary big endothelin and enhanced in early endothelial dysfunction.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Arteriosclerosis; Aspartic Acid Endopeptidases; Atrasentan; Coronary Circulation; Endothelin Receptor Antagonists; Endothelin-1; Endothelin-Converting Enzymes; Endothelins; Endothelium, Vascular; Glycopeptides; In Vitro Techniques; Male; Metalloendopeptidases; Myocardial Contraction; Oligopeptides; Peptides, Cyclic; Protein Precursors; Pulmonary Embolism; Pyrrolidines; Rabbits; Thromboxane B2; Vasoconstriction | 1998 |